FDA Greenlights Eli Lilly’s Oral GLP-1 Pill, Shaking Up $95 Billion Obesity Drug Market

Eli Lilly just got the FDA thumbs-up for its oral GLP-1 weight loss pill, stepping into a space dominated by injectable giants. This approval might shake up the obesity drug market, which is currently valued at about $95 billion.

Eli Lilly’s Bold Move Into Oral Weight Loss Treatments

The Food and Drug Administration’s recent approval of Eli Lilly’s GLP-1 oral pill marks a turning point in the battle over obesity drugs. Until now, the market has been ruled largely by injectable treatments, with Novo Nordisk’s semaglutide-based drugs like Wegovy and Ozempic leading the charge. But Lilly’s new pill offers a simpler alternative to weekly injections, potentially expanding patient access and convenience.

This is important. Injectable GLP-1 drugs have shown impressive results, but many patients hesitate because of needle aversion or injection schedules. A pill could lower those barriers.

But competition remains tough. Lilly’s injectable tirzepatide (marketed as Mounjaro) has already outpaced Novo’s Wegovy in weight loss effectiveness. A head-to-head study showed patients on tirzepatide shed about 15% of their body weight over a year, compared to 8% with Wegovy. The key difference is that tirzepatide targets two hunger hormones—GLP-1 and GIP—whereas Wegovy targets only GLP-1.

Market Dynamics: Lilly Gaining Ground on Novo Nordisk

Novo Nordisk led the obesity and diabetes drug market for years. Ozempic and Wegovy have been cash cows, driving billions in revenue. However, Novo’s growth has faced headwinds recently.

Supply shortages and an influx of lower-cost copycat semaglutide products from compounding pharmacies have chipped away at sales momentum.

Although the FDA ended semaglutide shortages and banned new compounded versions earlier this year, about one million U.S. patients still use these alternatives. That undercuts Novo’s pricing and market grip.

Novo responded by launching direct-to-patient discount platforms and partnering with WeightWatchers to make treatments more affordable. Plus, it’s developing higher-dose versions of Wegovy and an oral formulation expected to hit the U.S. Market in early 2026.

The Road Ahead: Competition Heating Up

Lilly’s oral pill is about to launch shortly after Novo’s oral Wegovy, setting the stage for a fierce race to capture the pill-based weight loss market. Analysts expect Lilly to capture nearly half of the $95 billion obesity drug market by 2030, thanks to its growing range of pills, injectables, and muscle-preserving antibody treatments.

Investors are paying attention. Goldman Sachs highlights Lilly’s strong position, noting it leads in most categories of anti-obesity treatments and sees the company maintaining a big lead for years. Ken Custer, Lilly’s executive vice president overseeing cardiometabolic health, has emphasized the company’s multi-pronged approach: offering a menu of options tailored to different patient needs.

Meanwhile, Novo Nordisk faces challenges beyond competition. The company recently agreed to lower drug prices for Medicare and Medicaid patients and expand coverage eligibility, moves expected to pressure global sales growth. But those deals also bring faster FDA review timelines and tariff exemptions, which could help Novo stay competitive.

Lilly’s growing portfolio and oral pill approval offer more convenience and options, which might be crucial as the market evolves.

Financial Stakes and Market Impact

Investors are closely watching quarterly earnings as these dynamics play out. Novo Nordisk’s earnings have been mixed, with some quarters beating expectations and others just meeting them. Its 2025 earnings per share estimates have softened slightly amid the pricing pressures and competition.

Lilly, on the other hand, is riding momentum from tirzepatide’s strong clinical data and growing market share. The company’s strategic investments in new metabolic drugs and oral formulations could translate into solid revenue growth and market dominance over the coming years.

However, the market is still unpredictable. Novo’s moves to contain copycat competition and adjust pricing, coupled with Lilly’s innovation pipeline, mean the obesity drug sector will continue to shift rapidly. In the end, success will go to those who balance effectiveness, convenience, and affordability.

Lilly’s FDA approval of an oral GLP-1 weight loss pill sets a new chapter in a high-stakes market. As both companies prepare to launch oral options, the race for dominance in obesity treatment is heating up like never before.